- Home
- ISPC vs XRTX Comparison
ISPC vs XRTX Comparison
Compare ISPC & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISPC | XRTX |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 4.3M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ISPC | XRTX |
|---|---|---|
| Price | $3.18 | $2.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 205.8K | 33.2K |
| Earning Date | 05-18-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,928,998.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $0.35 |
| 52 Week High | $6.77 | $3.60 |
Technical Indicators
Market Signals| Indicator | ISPC | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 47.35 |
| Support Level | $0.37 | $2.01 |
| Resistance Level | $4.49 | $2.93 |
| Average True Range (ATR) | 0.39 | 0.27 |
| MACD | -0.21 | -0.05 |
| Stochastic Oscillator | 16.35 | 24.62 |
Price Performance
Historical ComparisonAbout ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.